Dourthe et al. (37) analysed 51 patients with R/R BCP-ALL receiving commercial tisagenlecleucel and revealed that prior administration of blinatumomab was associated with a shorter EFS and reduced OS due to an increased risk of a CD19− relapse. Here, CD19 is linked to acute lymphoblastic leukemia.